TWST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Twist Bioscience Corp (TWST) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company has shown revenue growth and improved gross margins, it remains unprofitable with declining net income and EPS. The technical indicators suggest a neutral to slightly bullish trend, but the lack of strong proprietary trading signals and mixed sentiment in the biotech sector make this a hold rather than a buy.
The stock is showing a bullish trend with SMA_5 > SMA_20 > SMA_200 and MACD above 0, indicating positive momentum. RSI is neutral at 55.127, and the price is near the resistance level of R1: 50.051. However, the stock's recent candlestick pattern suggests limited short-term upside.
Analysts have raised price targets significantly, with most firms maintaining Outperform or Buy ratings.
Revenue increased by 16.89% YoY, and gross margin improved by 7.79% YoY.
The company is capitalizing on AI-driven drug discovery, which is a growing market.
The company remains unprofitable, with net income and EPS both declining YoY.
Hedge funds are selling the stock, with a significant increase in selling activity.
Broader biotech sector concerns, including potential delays in FDA approvals, may weigh on sentiment.
In Q1 2026, Twist Bioscience reported revenue growth of 16.89% YoY to $103.7 million and improved gross margins to 52.05%. However, the company remains unprofitable, with net income declining 3.44% YoY to -$30.5 million and EPS dropping 5.66% YoY to -0.5.
Analysts are bullish on TWST, with multiple firms raising price targets recently. The consensus price target is around $50-$52, driven by optimism about AI-driven drug discovery and NGS normalization. However, the stock's unprofitability and sector risks temper the enthusiasm.
